Loading...

WPD Pharmaceuticals Inc.

WBIO.CN•CNQ
Healthcare
Biotechnology
CA$0.07
CA$-0.12(-63.16%)

WPD Pharmaceuticals Inc. (WBIO.CN) Stock Overview

Explore WPD Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap324.8K
P/E Ratio-1207.41
EPS (TTM)$0.17
ROE0.01%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 Months$0.00
1 Year Target$0.15

WBIO.CN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of WPD Pharmaceuticals Inc. (WBIO.CN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.15.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1207.41 and a market capitalization of 324.8K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for WBIO.CNStats details for WBIO.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for WBIO.CNAnalyst Recommendations details for WBIO.CN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

CEO

Mariusz Olejniczak

Employees

16

Headquarters

789 West Pender Street, Vancouver, BC

Founded

2009

Frequently Asked Questions

;